Epidermal Growth Factor Receptor Antagonists For Treating Hypersecretion Of Mucus In The Lungs


The full document isn't yet available to us from the patent office.


Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The de-granulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.


Information currently unavailable.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Sep 17, 2008
  • Application: Aug 17, 1999
    EP EP 08009498 A
  • Priority: Aug 17, 1999
    EP EP 99943729 A
  • Priority: Aug 18, 1998
    US US 9702398 P

Download Citation

Sign in to the Lens